GenSpera Receives Key Patent on Prodrug for Prostate Cancer

GenSpera Receives Key Patent on Prodrug for Prostate Cancer
genspera patentGenSpera, Inc., a leader in developing prodrug therapeutics for the treatment of cancer, has announced that the United States Patent and Trademark Office (USPTO) issued the patent "Tumor Activated Prodrugs” for GenSpera’s G-202, the company’s lead drug candidate. This patents covers the development of G-202, a prodrug activated by Prostate Specific Antigen (PSA) and designed to deliver a thapsigargin (toxin) derivative selectively to prostate cancers. Researchers have isolated thapsigargin from the plant Thapsia garganica. This component inhibits the sarco/endoplasmic reticulum Ca2+ ATPase and induces cells to undergo apoptosis. By conjugating thapsigargin to peptides which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA), researchers could create prodrugs, a type of drug that alone does not have any pharmacological effect, but in the body is transformed into the active therapeutic. Once conjugated with the specific peptide, the drug can be targeted towards the malignant tissue, and upon internalization it releases the selected toxin, killing tumor cells. G-202 or mipsagargin, is a derivative of thapsigargin (12ADT) and is currently in Phase II
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *